Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$68.00

-7.99 (-10.51%)

09:09
11/25/16
11/25
09:09
11/25/16
09:09

Eli Lilly downgraded to Neutral from Overweight at Atlantic Equities

  • 04

    Dec

LLY Eli Lilly
$68.00

-7.99 (-10.51%)

11/23/16
JMPS
11/23/16
NO CHANGE
JMPS
Axovant not impacted by Lilly's solanezumab failure, says JMP Securities
JMP Securities analyst Jason Butler said Axovant Sciences (AXON) is not impacted by Eli Lilly's (LLY) solanezumab. The analyst said solanezumab has a very different mechanism of action, and unlike solanezumab, Axovant's has already prospectively demonstrated statistically significant improvements in cognition and function in a pivotal trial. Butler recommends buying Axovant on weakness and reiterates his Outperform rating and $36 price target.
11/25/16
RHCO
11/25/16
NO CHANGE
Target $101
RHCO
Buy
Eli Lilly price target lowered to $101 from $107 at SunTrust
SunTrust analyst John Boris removed solanezumab, which he had viewed as a "high risk/high reward" asset, from his model after the company reported a Phase 3 study showed that the drug failed to slow loss of cognitive ability in patients with mild Alzheimer's disease. Boris cut his price target on Lilly shares to $101 from $107, but recommends taking advantage of weakness in the shares, on which he keeps a Buy rating.
11/25/16
UBSW
11/25/16
NO CHANGE
Target $70
UBSW
Neutral
Eli Lilly price target lowered to $70 from $82 at UBS
UBS analyst Marc Goodman lowered his price target on Eli Lilly to $70 from $82 following the halt of its solanezumab drug trial for Alzheimer's. The analyst removed his sales estimates for solanezumab and said that without its contribution he is less optimistic for top-line growth. Goodman recommends investors stay on the sidelines and reiterated his Neutral rating on Eli Lilly shares.
11/25/16
BARD
11/25/16
NO CHANGE
Target $29
BARD
Outperform
Lilly trial failure has little to do with Axovant Sciences, says Baird
Baird analyst Brian Skorney said Eli Lilly's (LLY) solanezumab drug trial failure has little to do with Axovant Sciences (AXON) drug trial for Alzheimer's. The analyst said Lilly's failure is a reminder of the difficulty of the disease, but the two company's drugs are very different and meant to have very different effects. Skorney reiterated his Outperform rating and $29 price target on Axovant shares.

TODAY'S FREE FLY STORIES

08:40
02/27/17
02/27
08:40
02/27/17
08:40
General news
U.S. durable goods orders rebounded 1.8% in January »

U.S. durable goods orders…

ERIC

Ericsson

$6.45

-0.08 (-1.23%)

, QCOM

Qualcomm

$57.22

0.08 (0.14%)

08:39
02/27/17
02/27
08:39
02/27/17
08:39
Conference/Events
Drexel Hamilton Events at Mobile World Congress »

Meetings with various…

ERIC

Ericsson

$6.45

-0.08 (-1.23%)

QCOM

Qualcomm

$57.22

0.08 (0.14%)

CSCO

Cisco

$34.32

0.28 (0.82%)

SNCR

Synchronoss

$30.49

-0.37 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 03

    Mar

  • 13

    Mar

  • 29

    Mar

REGN

Regeneron

$361.01

0.05 (0.01%)

, SNY

Sanofi

$42.70

0.19 (0.45%)

08:39
02/27/17
02/27
08:39
02/27/17
08:39
Hot Stocks
Regeneron, Sanofi to present new data on DUPIXENT at AAD »

Regeneron Pharmaceuticals…

REGN

Regeneron

$361.01

0.05 (0.01%)

SNY

Sanofi

$42.70

0.19 (0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

  • 09

    Mar

  • 17

    Mar

  • 29

    Mar

LAUR

Laureate Education

$13.24

0.06 (0.46%)

08:38
02/27/17
02/27
08:38
02/27/17
08:38
Initiation
Laureate Education initiated  »

Laureate Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$21.60

0.02 (0.09%)

08:37
02/27/17
02/27
08:37
02/27/17
08:37
Initiation
Invitation Homes initiated  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNB

F.N.B.

$15.65

-0.02 (-0.13%)

, YDKN

Yadkin Financial

$33.42

-0.14 (-0.42%)

08:37
02/27/17
02/27
08:37
02/27/17
08:37
Hot Stocks
F.N.B. receives final regulatory approvals for proposed merger of Yadkin Financial »

F.N.B. (FNB) announced…

FNB

F.N.B.

$15.65

-0.02 (-0.13%)

YDKN

Yadkin Financial

$33.42

-0.14 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENB

Enbridge

$41.34

-0.37 (-0.89%)

, SE

Spectra Energy

$40.68

-0.32 (-0.78%)

08:36
02/27/17
02/27
08:36
02/27/17
08:36
Hot Stocks
Enbridge, Spectra Energy complete merger »

Enbridge (ENB) announced…

ENB

Enbridge

$41.34

-0.37 (-0.89%)

SE

Spectra Energy

$40.68

-0.32 (-0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

OTIV

On Track Innovations

$1.99

-0.08 (-3.86%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Hot Stocks
On Track Innovations announces appointment of VP of Sales »

On Track Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$52.63

0.12 (0.23%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EV

Eaton Vance

$46.96

-0.24 (-0.51%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Hot Stocks
Eaton Vance expands presence in Japan »

Eaton Vance announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRI

Silver Standard

$11.53

0.63 (5.78%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Recommendations
Silver Standard analyst commentary  »

Silver Standard reproted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$57.81

-0.68 (-1.16%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Hot Stocks
Buffett says Wells Fargo made 'huge mistake' »

Warren Buffett said on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

XLE

Energy Select Sector SPDR

$70.99

-0.67 (-0.93%)

08:35
02/27/17
02/27
08:35
02/27/17
08:35
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:35
02/27/17
02/27
08:35
02/27/17
08:35
General news
N.Y. FX Outlook »

N.Y. FX Outlook: The…

XLY

Consumer Discretionary Sector SPDR

$86.92

0.4 (0.46%)

08:34
02/27/17
02/27
08:34
02/27/17
08:34
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENFC

Entegra Financial

$23.15

0.05 (0.22%)

08:34
02/27/17
02/27
08:34
02/27/17
08:34
Hot Stocks
Entegra Financial completes purchase of 2 branches in Northern Georgia »

Entegra Bank, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$52.43

0.11 (0.21%)

08:34
02/27/17
02/27
08:34
02/27/17
08:34
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$51.59

0.77 (1.52%)

08:33
02/27/17
02/27
08:33
02/27/17
08:33
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMPE

Ampio

$0.80

-0.0312 (-3.75%)

08:33
02/27/17
02/27
08:33
02/27/17
08:33
Hot Stocks
Ampio: OTAT provides guidance for path to approval of Ampion »

Ampio Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLSN

Celsion

$0.21

-0.0229 (-9.83%)

08:33
02/27/17
02/27
08:33
02/27/17
08:33
Hot Stocks
Celsion sees OVATION study to be fully enrolled, data to come in Q2 »

Celsion Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$55.28

0.19 (0.34%)

08:33
02/27/17
02/27
08:33
02/27/17
08:33
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$74.78

0.36 (0.48%)

08:33
02/27/17
02/27
08:33
02/27/17
08:33
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$30.49

-0.37 (-1.20%)

08:32
02/27/17
02/27
08:32
02/27/17
08:32
Hot Stocks
Synchronoss names John Frederick as CFO, effective immediately »

Synchronoss Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

IWM

iShares Trust Russell 2000 Index Fund

$138.65

-0.1 (-0.07%)

08:32
02/27/17
02/27
08:32
02/27/17
08:32
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$207.93

0.11 (0.05%)

08:32
02/27/17
02/27
08:32
02/27/17
08:32
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.